Medtronic plc, a global leader in healthcare technology, today announced that Ryan Weispfenning, vice president and head of investor relations, has elected to join its Diabetes business to establish and lead the investor relations function for MiniMed, the planned New Diabetes Company. Ryan brings over 25 years of experience with Medtronic to his new role.

医疗技术领域的全球领导者美敦力公司今日宣布，副总裁兼投资者关系主管瑞安·魏斯芬宁已选择加入其糖尿病业务部门，为计划中的新糖尿病公司MiniMed建立并领导投资者关系职能。瑞安在美敦力拥有超过25年的经验，将携此丰富经验履新。

He has been a member of the Medtronic investor relations team for the past 17 years, including leading the function for more than a decade. He helped guide the company through dynamic business environments while fostering strong relationships with analysts, investors, and other stakeholders around the world.

在过去的17年中，他一直是美敦力投资者关系团队的成员，其中包括十多年领导该职能。他在帮助公司应对动态商业环境的同时，与全球的分析师、投资者及其他利益相关者建立了牢固的关系。

He will be a key strategic partner to the MiniMed executive team and board of directors, and his experience and leadership will be important for both Medtronic and MiniMed as the business works toward its intended separation of MiniMed into an independent, publicly traded company..

他将成为MiniMed执行团队和董事会的关键战略伙伴，他的经验和领导力对美敦力和MiniMed都非常重要，因为该业务正朝着将MiniMed分拆为一家独立的上市公司这一目标努力。

“After leading Medtronic investor relations for the past decade, I am now honored to help establish the investor relations function for MiniMed as we prepare for its intended separation into an independent, public company,” said Ryan Weispfenning. “This is a pivotal moment for the Diabetes business, and I look forward to partnering with the MiniMed leadership team and engaging with the investor community to articulate our long-term strategy, growth opportunities, and commitment to improving outcomes for people living with diabetes worldwide.”.

“在过去的十年里领导美敦力投资者关系工作后，我非常荣幸能够帮助MiniMed建立投资者关系职能，为MiniMed即将独立成为一家上市公司做准备。”Ryan Weispfenning表示，“这是糖尿病业务的关键时刻，我期待与MiniMed的领导团队合作，并与投资者群体互动，阐明我们的长期战略、增长机会以及致力于改善全球糖尿病患者生活状况的承诺。”

The company also announced that Ingrid Goldberg will join Medtronic as vice president and head of investor relations. Goldberg brings more than 20 years of industry experience, spanning the financial, medical device, and life science sectors.

公司还宣布，英格丽·戈德伯格将加入美敦力，担任副总裁兼投资者关系主管。戈德伯格拥有超过20年的行业经验，横跨金融、医疗器械和生命科学领域。

Most recently, Goldberg served as vice president of finance and investor relations at Novocure, where she led the investor relations, communications, and business development functions. Prior to Novocure, Goldberg held leadership positions at Abiomed, leading investor relations through a period of exceptional expansion and contributing to the company’s more than 15x increase in market capitalization.

最近，戈德伯格在Novocure担任财务及投资者关系副总裁，领导了投资者关系、沟通和业务发展职能。在加入Novocure之前，戈德伯格在Abiomed担任领导职务，带领投资者关系团队经历了一段非凡的扩张期，并为公司市值增长超过15倍做出了贡献。

Goldberg also led the investor relations function at gene and cell therapy pioneer, Bluebird Bio. Before transitioning to corporate healthcare, Goldberg spent a decade at Bank of America Merrill Lynch..

戈德伯格还在基因和细胞治疗先驱蓝鸟生物公司领导了投资者关系部门。在转型到企业医疗保健领域之前，戈德伯格在美银美林工作了十年。

Goldberg holds degrees from Princeton University and the MIT Sloan School of Management. She will be based in Boston, where she lives with her husband, Scott, and their two daughters.

戈德伯格持有普林斯顿大学和麻省理工学院斯隆管理学院的学位。她将常驻波士顿，与丈夫斯科特和两个女儿一起生活。

“I am thrilled to join Medtronic, an organization whose work transforms patient lives every day,” said Goldberg. “The company’s compelling product portfolio is inspiring, and I am eager to share the progress and innovation that define Medtronic and the people we serve. It is a privilege to contribute to a company so deeply committed to improving human health.”.

“我非常高兴加入美敦力，这是一家每天都在改变患者生活的企业，”戈德堡说。“这家公司令人振奋的产品组合让我感到鼓舞，我渴望分享定义美敦力及其服务人群的进步与创新。能够为一家如此致力于改善人类健康的公司做出贡献，是一种荣幸。”

These changes will be effective on Dec. 8. Ryan will support Ingrid and Medtronic for a period of time to ensure a seamless transition.

这些变更将于 12 月 8 日生效。Ryan 将在一段时间内为 Ingrid 和美敦力提供支持，以确保无缝过渡。

About Medtronic

美敦力公司简介

Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries.

大胆思考。更果敢的行动。我们是美敦力。美敦力公司总部位于爱尔兰戈尔韦，是全球领先的医疗技术公司，通过寻找并发现解决方案，大胆应对人类面临的最严峻的健康问题。我们的使命——减轻病痛、恢复健康、延长生命——将遍布150多个国家的95,000多名充满热情的员工团结在一起。

Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day.

我们的技术和治疗手段涵盖70种健康状况，包括心脏设备、手术机器人、胰岛素泵、手术工具、患者监测系统等。凭借我们多元化的知识、无尽的好奇心和帮助所有有需要的人的愿望，我们提供了创新的技术，每秒、每小时、每一天都在改变着两个人的生活。

Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit .

期待我们带来更多精彩，因为我们致力于推动以洞察力为基础的护理、以人为本的体验，以及为我们的世界创造更好的成果。在我们所做的每一件事中，我们都在创造非凡。欲了解有关美敦力的更多信息，请访问。

www.Medtronic.com

www.美敦力.com

and follow on

并关注

LinkedIn

领英

.

。

About the Diabetes Business at Medtronic

关于美敦力的糖尿病业务

Medtronic Diabetes is on a mission to make diabetes more predictable, so everyone can embrace life to the fullest with the most advanced diabetes technology and always-on support when and how they need it. We've pioneered first-of-its-kind innovations for over 40 years and are committed to designing the future of diabetes management through next-generation sensors (CGM), intelligent dosing systems, and the power of data science and AI while always putting the customer experience at the forefront..

美敦力糖尿病事业部致力于让糖尿病变得更可预测，使每个人都能通过最先进的糖尿病技术和随时随地的支持，充分享受生活。四十多年来，我们率先推出了多项首创的创新技术，并承诺通过下一代传感器（CGM）、智能给药系统以及数据科学和人工智能的力量，设计糖尿病管理的未来，同时始终将客户体验置于首位。

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

任何前瞻性陈述均受风险和不确定性的影响，例如美敦力公司向证券交易委员会提交的定期报告中所述的风险和不确定性。实际结果可能与预期结果有重大差异。

Contacts:

联系人：

Erika Winkels

埃丽卡·温克尔斯

Public Relations

公共关系

+1-612-558-8932

+1-612-558-8932

Ryan Weispfenning

瑞安·魏斯芬宁

Investor Relations

投资者关系

+1-763-505-4626

+1-763-505-4626